NOVACYT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.819 EUR | +2.89% |
|
-1.33% | +14.87% |
| 04-19 | Novacyt: confident ahead of DHSC trial | CF |
| 04-19 | Novacyt expects court to dismiss application by UK DHSC | AN |
| Sales 2021 | 95.78M 102M 8.2B | Sales 2022 | 21.04M 22.5M 1.8B | Capitalization | 76.79M 82.1M 6.57B |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.62M -771M | Net income 2022 | -25M -26.73M -2.14B | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 107M 8.55B | Net cash position 2022 | 86.29M 92.27M 7.39B | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 day | +2.89% | ||
| 1 week | -1.33% | ||
| Current month | +58.41% | ||
| 1 month | +58.57% | ||
| 3 months | +47.57% | ||
| 6 months | +74.11% | ||
| Current year | +14.87% |
1 week
0.75
0.85
1 month
0.510.87
Current year
0.490.87
1 year
0.421.00
3 years
0.426.08
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
James McCarthy
CEO | Chief Executive Officer | 58 | 04/01/21 |
Steven Gibson
DFI | Director of Finance/CFO | 41 | 31/03/17 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Heath
BRD | Director/Board Member | 76 | 28/06/15 |
John Brown
BRD | Director/Board Member | 69 | 07/09/23 |
Lyn Rees
BRD | Director/Board Member | 51 | 07/09/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.819 | +2.89% | 159,483 |
| 25/04/24 | 0.796 | -5.24% | 131,739 |
| 24/04/24 | 0.84 | +3.70% | 294,239 |
| 23/04/24 | 0.81 | +3.85% | 341,386 |
| 22/04/24 | 0.78 | -6.02% | 634,794 |
Real-time Euronext Paris, April 26, 2024 at 04:28 pm
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
25/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.87% | 61.68M | |
| -28.51% | 925M | |
| -20.60% | 128M | |
| -7.82% | 67.46M | |
| +6.64% | 60.58M | |
| +0.60% | 51.45M |
- Stock Market
- Equities
- ALNOV Stock
